Cite
HARVARD Citation
Rowan, C. et al. (n.d.). P481 Induction treatment with subcutaneous rather than intravenous ustekinumab is associated with comparable circulating drugs levels and early clinical response. Journal of Crohn's and colitis. pp. S347-S348. [Online].